CGChandrashekaran Girish

Chandrashekaran Girish

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chandrashekaran Girish has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunogenicity, Efficacy and Safety of Covishield vaccine in Non- dialysis Chronic Kidney Disease Patients in Comparison with Healthy Subjects; A Clinical Cohort Study

    by Vinusha Vijayakumar, Chandrashekaran Girish, Sreejith Parameswaran, Chanaveerappa Bammigatti Bammigatti, Ramakrishnan Jayalakshmy

    Background: The incidence of chronic kidney disease (CKD) is more than ten percent globally and they show higher mortality with COVID-19. The immune response of CKD patients to Covishield vaccine may vary. Therefore, understanding vaccine efficacy in this population is critical. Aim: To compare the immunogenicity, safety and efficacy of Covishield vaccine in Non-Dialysis CKD patients with healthy subjects. Methods: Non dialysis CKD patients represent Cohort one and healthy participants represent cohort two. Eligible participants were recruited between 21 and 90 days post second dose of Covishield vaccination. IgG and IFN gamma levels were measured to assess immunogenicity. Any adverse effects were documented in an Adverse Event Following Immunization form through direct or telephonic interview. The occurrence of COVID-19 illness was used to assess efficacy. Data analysis was done by using t-tests and Chi-square tests. Results: We recruited 40 non-dialysis CKD patients and 38 healthy participants. IgG (p = 0.072) and IFN gamma levels (p = 0.339) were not statistically different between these groups. The ADR profile was also similar between the two groups. None of the participants developed COVID-19 illness during the study period. Conclusion: Non-dialysis CKD patients showed similar immunogenicity, safety, and efficacy to the Covishield vaccine as compared to healthy participants. Hence, non-dialysis CKD patients can follow the routine vaccination schedule.

  • Open Access

    Plant-based vaccines against viral hepatitis: A panoptic review

    by Devanathan Reka, Chandrashekaran Girish

    The traditional vaccines against hepatitis have been instrumental in reducing the incidence of some types of viral hepatitis; however, the need for cost-effective, easily distributable, and needle-free vaccine alternatives has led to the exploration of plant-based vaccines. Plant-based techniques offer a promising avenue for producing viral hepatitis vaccines due to their low-cost cultivation, scalability, and the potential for oral administration. This review highlights the successful expression of hepatitis B surface antigens in plants and the subsequent formation of virus-like particles, which have shown immunogenicity in preclinical and clinical trials. The challenges such as achieving sufficient antigen expression levels, ensuring consistent dosing, and navigating regulatory frameworks, are addressed. The review considers the potential of plant-based vaccines to meet the demands of rapid vaccine deployment in response to outbreaks and their role in global immunization strategies, particularly in resource-limited settings. This review underscores the significant strides made in plant molecular farming and the potential of plant-based vaccines to complement existing immunization methods against viral hepatitis.


  • Open Access

    A Cross-Sectional Trait Versus State Biomarker Analysis of Inflammatory Cytokines and miRNAs in Patients with Major Depressive Disorder

    by Christopher Rockson, Chandrashekaran Girish, Harivenkatesh Natarajan, Vikas Menon

    Background: Inflammatory cytokines are associated with the pathophysiology of major depressive disorder (MDD). Nevertheless, whether they are trait or state biomarkers remains unclear. We aimed to assess and compare selected cytokines, miRNAs, and oxidative stress biomarker levels between patients with MDD, first-degree relatives (FDRs), and unrelated healthy controls (UHCs). Methods: Using a cross-sectional design, we recruited patients with MDD, their FDRs and age, gender, body mass index-matched UHCs. Serum levels of IL-6, IL-1β, TNF-α, hs-CRP, and IL-10 were evaluated using the Enzyme-Linked Immunosorbent Assay (ELISA) method. We quantified the gene expressions of plasma miR-16, miR-132, and miR-1202 using Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). We estimated the total oxidant status and total antioxidant status levels in the serum by ELISA. We used sequential multiple linear regression analysis to find the association between MDD vs. UHCs (model 1), FDRs vs. UHCs (model 2), and MDD vs. FDRs (model 3) after adjusting for age, gender, and BMI as covariates. Results: The study involved 50 patients with MDD (mean age = 34.7 ± 10.1 years), 31 FDRs (mean age = 32.7 ± 12.2 years), and 50 UHCs (mean age = 34.1 ± 10.3 years). Patients with MDD had higher levels IL-6 (β = 6.04; 95% CI; 1.60 to 10.49; p = 0.008) and downregulated miR-1202 (β = –0.38; 95% CI: –0.70 to –0.06; p = 0.02) compared to FDRs with statistically significant differences. Conclusion: The higher levels of serum IL-6 and downregulated plasma miR-1202 expression in patients with MDD compared to FDRs may be a state biomarkers in MDD. However, an adequately powered study can answer these questions with certainty.


  • Discovering vaccines: the trial tale

    by Vijayakumar Vinusha, Chandrashekaran Girish

    This paper reviews the importance of vaccine trials to public health. Vaccines are developed to build immunity to disease, which have helped to completely eliminate smallpox, and reduced incidence of polio and measles. A variety of breakthroughs made many years ago, such as the smallpox vaccine by Edward Jenner and the discoveries by Louis Pasteur, also set the stage for modern international immunization programs. A few events, such as the licensing of the polio vaccine and the passage of the Vaccination Assistance Act helped to improve the study of vaccines. In particular, vaccine trials may be RCTs, cluster trials, or cohort studies. The sample sizes will depend on the objectives, which would include the primary and secondary endpoints. The population under study and the geographical location also affect the trial design. Preclinical evaluation is usually the starting point of vaccine trials, where the safety and efficacy are researched on animal models or cell cultures. Animal models are selected based on their similarity to the target disease. Safety is checked in Phase I, efficacy in Phase II, and both in Phase III. Phase IV is a post-marketing surveillance of the vaccine’s safety in real life. Regulatory bodies play a very vital role in ensuring that vaccines adhere to a very high standard of safety and efficacy, such as the FDA, as required. Ethical considerations, such as informed consent and the rights of participants, are innate and are implemented and enforced through laws, regulations, and ethical committees. Vaccine studies vary from the drug studies as it is focused on preventing illness in healthy patients as opposed to cure of diseases in drug trials. The dramatic development in vaccine research was driven by recent pandemics, with parallel processing and data collection in real time. Clinical trials of the vaccine are a foundation stone of public health in the reduction of sickness, offering immunity to diseases, and continuing the fight against infectious diseases. The present review is aimed at describing vaccine trials and their important aspects.


  • Open Access

    Effect of Cleistanthus collinus on the reproductive system of male Wistar rats

    by Subramanian Umamaheswari, Chandrashekaran Girish, Debdatta Basu

    Objective: Plants are widely used in the traditional system of medicine and many of them can adversely affect the reproductive system. Cleistanthus collinus is a plant containing many active phytochemicals, which have the potential to be developed as a drug. The present study was aimed to evaluate the effects of an aqueous extract of C. collinus on the male reproductive system. Methods: Male Wistar rats were treated with different doses of C. collinus (200 and 400 mg/kg, orally), or with saline for 28 days and its effect on the reproductive system was assessed. Cyclophosphamide (100 mg/kg, weekly, i.p), a well-known reproductive toxicant, was used as a positive control. Results: There was a significant reduction in sperm count and motility with C. collinus treatment, along with the destruction of primary spermatocytes, spermatids and reduced thickness of the basal layer. The LH, FSH and testosterone levels were reduced significantly. A reduction in the area of seminiferous tubules indicates the destruction of germ cells and Sertoli cells. C. collinus treatment increased the oxidative stress, evidenced by elevated malondialdehyde levels along with a reduction in catalase and GSH activities. The expression of BAX, BCL-2 and p53 was observed in spermatocytes, indicating an increase in apoptosis. Conclusions: C. collinus can produce male reproductive toxicity, which may be mediated through alterations in hormonal levels, which in turn interferes with spermatogenesis. It may increase the expression of apoptotic factors and deplete protective antioxidant enzymes in the testis.


  • Open Access

    Role of immune dysfunction in drug induced liver injury

    by Chandrashekaran Girish, Sukumaran Sanjay

    Drug-induced liver injury (DILI) is one of the leading causes of liver failure and withdrawal of drugs from the market. A poor understanding of the precipitating event aetiology and mechanisms of disease progression has rendered the prediction and subsequent treatment intractable. Recent literature suggests that some drugs can alter the liver’s repair systems resulting in injury. The pathop hysiology of DILI is complex, and immune dysfunction plays an important role in determining the course and severity of the disease. Immune dysfunction is influenced by the host response to drug toxicity. A deeper understanding of these processes may be beneficial in the management of DILI and aid in drug devel opment. This review provides a structured framework presenting DILI in three progressive stages that summarize the interplay between drugs and the host defence networks.


  • Open Access

    Efficacy of Phyllanthus niruri on improving liver functions in patients with alcoholic hepatitis

    by Karri Sowjanya, Chandrashekaran Girish, Chanaveerappa Bammigatti, Nakka Chandrasekhar Prasanna Lakshmi

    INTRODUCTION: Phyllanthus niruri, a traditional herbal medicine, was found to be hepatoprotective as evidenced by several preclinical and clinical studies. However, to the best of our knowledge, there are no clinical trials available to date to evaluate its efficacy in alcoholic hepatitis. MATERIALS AND METHODS: The present study is a block randomized, double-blind, parallel-arm placebo-controlled trial that was designed to assess the efficacy of P. niruri on the liver and renal function parameters, total oxidant and antioxidant levels in alcoholic hepatitis patients in comparison to placebo over a 4-week period. Patients were screened by CAGE questionnaire, and those with a confirmed diagnosis of mild–moderate alcoholic hepatitis based on laboratory findings and Maddrey's discriminant function score were randomly allocated to treatment and placebo arms. Clinical assessments were done at baseline, 2 weeks, and 4 weeks. A total of 454 patients were screened and 100 eligible patients were recruited for the study, and 71 were analyzed using the modified intention-to-treat approach. RESULTS: Serum levels of liver and renal function parameters failed to demonstrate significant improvement with P. niruri. However, there was a statistically significant increase in the level of total antioxidants with P. niruri (P = 0.034) with an additional appetite stimulant activity (P = 0.03) in 4 weeks. CONCLUSION: A 4-week administration of P. niruri in mild–moderate alcoholic hepatitis patients showed an improvement in the total antioxidant levels with an appetite stimulant activity compared to a placebo.


  • Quercetin modulates NRF2 and NF-κB/TLR-4 pathways to protect against isoniazid- and rifampicin-induced hepatotoxicity in vivo

    by Sukumaran Sanjay, Chandrashekaran Girish, Pampa Ch Toi, Zachariah Bobby

    Isoniazid and rifampicin are crucial for treating tuberculosis (TB); however, they can cause severe hepatotoxicity leading to liver failure. Therapeutic options are limited and ineffective. We hypothesized that prophylaxis with quercetin attenuates isoniazid- and rifampicin-induced liver injury. We randomly divided Wistar rats into seven groups (n = 6). The animals received isoniazid and rifampicin or were co-treated with quercetin or silymarin for 28 days. The protective effect of quercetin was assessed using liver function tests and liver histology. Nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways were explored to elucidate the mechanism of action. Quercetin co-administration prevented the elevation of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and bilirubin compared with isoniazid and rifampicin treatment alone. In the histological analysis, we observed that quercetin prophylaxis lessened the severity of hepatic necrosis and inflammation compared with the anti-TB drug–treated group. Quercetin attenuated anti-TB drug–induced oxidative stress by increasing NRF2 activation and expression, boosting endogenous antioxidant levels. Additionally, quercetin blocked inflammatory mediators high mobility group box-1 (HMGB-1) and interferon γ (IFN-γ), inhibiting activation of the NF-κB/ toll like receptor 4 (TLR-4) axis. Quercetin protects against anti-TB liver injury by activating NRF2 and blocking NF-κB/TLR-4.